Prior to founding health benefits platform Jiff (which was acquired by Castlight in 2017), Newell worked for years in the remote care monitoring and chronic disease management space.
Sen. Dick Durbin, D-Illinois, was also among four signatories to a letter to FDA Commissioner Scott Gottlieb calling on the agency to speed up approvals of generic versions of insulin products.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The new version, sold under its generic name, would be priced 50 percent lower than the branded version, at $137.35 per vial or $265.20 for a five-pack of pens.
Insulin prices have shot up nearly 600 percent, according to a congressional study, leading to potentially deadly rationing by many patients.
Interviews with Glooko's previous CEO, new CEO and a Novo Nordisk executive show that the two company's messaging around the development of a smart insulin pen is not aligned.
The pharma industry as a whole has cranked up political contributions and lobbying. Meanwhile, despite much talk about change, Congress and the Trump administration have done little to control drug prices or threaten drug-company profits.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Although diabetes management through insulin has been a focus of the company, it is also developing tools to support other injectable medication such as fertility drugs and growth hormones.
The United States is one of the few developed countries without regulations on prescription drug pricing.
Although drug price legislation has stalled in some states, some advocates say there's plenty of grass-roots support for this legislation on insulin prices but that advocacy organizations are not listening to the right people.
Novo Nordisk has axed an experimental insulin pill from its pipeline citing commercial — not medical — reasons. It's the latest in a complex debate raging over the price of insulin and the cost of progress.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
“Computer algorithms facilitate doing the right thing,” said Dr. Joseph A. Aloi, professor of endocrinology and metabolism at Wake Forest Baptist Medical Center in Winston-Salem, North Carolina.
It's worthwhile to resurrect a 2015 infographic from the Alliance of Community Health Plans that shows which insulin analogs are spiking most in price.
The company's using the funding to help commercialize its shelf-stable glucagon pen for hypoglycemia in diabetics.
Thermalin Diabetes is picking up steam – and funding – as it develops a more concentrated and faster-acting version of insulin. The Boston and Cleveland-based company just raised $5.9 million from private investors in the first tranche of a Series B round. To date, it has raised about $15 million in equity and $8 million in NIH […]
Everyone likes to talk about funding for digital health – Y Combinator is doing biotech now! Andreesen Horowitz gets into health tech! Deals and dollars look great in Q1 2014! It’s not as easy to make cheery slide decks about funding for the rest of the healthcare startup world: pharma, medical devices and bio tech […]